Industry news that matters to you.  Learn more

Archives for February 2012

Horizon and UK NEQAS ICC Announce Partnership to Improve Accuracy of Lung Cancer Diagnostic Testing

Horizon Diagnostics (HorizonDx), a division of Horizon Discovery, a leading provider of research tools to support the development and prescription of personalized medicines, recently announced it has signed a strategic partnership agreement with UK NEQAS. The partnership will focus on the development of genetically defined reference standards for novel lung cancer biomarkers.

Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-inclass disease–modifying therapeutic protein being developed for the treatment of Parkinson’s Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro Blood Test as it relates to Parkinson’s disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

NYAS Symposium Review: Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease

The New York Academy of Sciences (NYAS) symposium, Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease, was held last week Tuesday. About 150 people were in attendance consisting of a mix of academic and industrial researchers. [On a side note, the NYAS symposium office is located on the 40th floor of 7 World Trade Center and the views of New York city are spectacular.]